Investigational antibiotic, Taksta, granted QIDP

Cempra, Inc. announced recently that the U.S. Food and Drug Administration (FDA) has granted a qualified infectious disease product (QIDP) designation to Cempra's investigational antibiotic product candidate, Takstaa (CEM-102, sodium fusidate, the sodium salt of fusidic acid). The designation is for Taksta oral tablets for the indication of acute bacterial skin and skin structure infections ["]